The American company is the only pharmaceutical company in the world, which has made only one dose Corona vaccine. Johnson & Johnson has told the Indian regulator that it will soon start its bridging clinical trial in India. According to government sources, in a letter to the Central Drugs Standard Control Organization (CDSCO), it has written to submit an application in this regard soon. Significantly, in view of the second wave of corona in the country, the need to increase the production of vaccine is felt, as many states are complaining about the depletion of the vaccine stock.
The bridging trial is a clinical trial, in which the regulator asks the company to register only a limited number of partners. This trial is only to see how safe the vaccine is and this gives an idea of its immunogenicity. In India, Johnson & Johnson has already tied up with Biologics E to increase its vaccine production capacity.